In a study published in eClinicalMedicine, researchers at the German Diabetes Center (DDZ) show that automated insulin ...

Type 1 diabetes is a lifelong condition in which the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. The loss of these cells leads to high blood sugar ...

Researchers found that higher urinary levels of caffeine and specific metabolites, especially in men, were significantly ...

For years, metformin has been the go-to first-line oral medication for patients newly diagnosed with type 2 diabetes. But ...

Medicaid enrollees with type 2 diabetes face restricted access to newer classes of first-line medications, especially in ...

TYPE 2 diabetes (T2D) is not only a metabolic disorder but is increasingly recognised as a risk factor for cognitive decline and dementia. As newer classes of glucose-lowering drugs become more widely ...

Delhi: The Central Drugs Standard Control Organization (CDSCO) has banned the manufacture, sale, and distribution of certain widely used strengths of fixed dose combinations (FDCs) in the ...

Eli Lilly says it plans to submit orforglipron to the U.S. Food and Drug Administration for approval as a Type 2 diabetes treatment in 2026. For weight management, it plans to submit the drug to ...

By focusing on natural ingredients, GF Caps aims to provide an effective alternative to conventional diabetes medications, which can often come with unwanted side effects. Each ingredient is selected ...

Common diabetes drugs tied to brain health The research, published in JAMA Neurology , draws on Medicare data from tens of thousands of older adults diagnosed with Type 2 diabetes.

The trial included 559 participants. None of them had taken a diabetes medication for 3 months prior or used insulin therapy. The primary goal of the study was to test for glucose control. However, ...

Eli Lilly intends to submit Orforglipron for weight management to global regulatory agencies by the end of 2025, as well as for type 2 diabetes treatment in 2026, according to the company.